x-octo home Business judgment on AI products
中文

Real-revenue cases

We Raised $21M, Built A Home Blood Testing Device Took It To Market

Nice-to-have

A Swiss startup selling a home blood-testing device: users draw a sample at home, get results and explanations on their phone. Revenue comes from hardware and test consumables, with pharmacies as the first channel.

Founder interview, self-reported 约 3 年(2018 年 5 月成立,2021 年 9 月报道时刚进入市场)药房合作线下旗舰店社交媒体
Primary source
View original

01

Real-demand verdict

Real-demand verdict

Nice-to-have

It replaces the hassle of going to a clinic or lab for blood work, so the need is real. But self-paid home testing is a discretionary purchase rather than a necessity, and there is no data on whether users keep buying consumables, so it reads as want rather than real.

How it makes money

Sells the testing device and follow-on test consumables to individuals, and supplies B2B partners like pharmacies that use test results to support their supplement advice. Unit pricing and repeat-purchase structure are not disclosed.

What old behavior it replaces

Going to a clinic or lab for a blood draw, waiting for results, then getting a doctor to interpret them.

02

Where the first customers came from

Signed 8 pharmacies in and around Vienna as B2B channel partners in the first month of launch.

Acquisition channels 药房合作线下旗舰店社交媒体

03

Tactics you can copy

  1. 01Start with pharmacies: they lend credibility, explain the product in person, and can use test results to sell more, turning the channel into a salesforce.
  2. 02Open one flagship store in a core city so people can touch the product, solving the awareness problem for a brand-new category.
  3. 03Hide the hardware, biotech and software complexity; the front end is one simple test plus instant interpretation on the phone.
  4. 04Enter through a heavily regulated market and get ISO and CE certification early, turning compliance into a moat.
Moving it to an AI business

For AI founders: the pattern of recruiting trusted offline channels to explain the product, then arming those channels with data or results to help them sell, transfers to AI health and AI diagnostics products. Note that the hardware-plus-medical-compliance path is heavy and not copyable by a pure-software AI product.

04

Evidence and limits

Self-reported numbers are unaudited — treat them as leads, not facts
Founder interview, self-reported

Revenue basis · Founder self-reported, unaudited (see source page)

What evidence is missing

The $20K/month figure is founder self-reported and unaudited; set against $21M raised and 70 employees, both the revenue definition and its scope are unclear.
No device price, consumable repurchase rate, or customer lifetime value is disclosed, so unit economics cannot be assessed.
Claims of profitability within two years and large US partners awaiting approval are founder statements with no third-party evidence.